NCR3 and neoplasm: Upon investigation of NKp30 and a soluble form of its tumor-derived ligand B7-H6, Semeraro et al. suggest that NK cell activity may be improved by the neutralization of sB7-H6 in conjunction with activating NKp30 mAbs [162].